Thrivent Financial for Lutherans Has $4.97 Million Position in Henry Schein, Inc. $HSIC

Thrivent Financial for Lutherans decreased its position in Henry Schein, Inc. (NASDAQ:HSIC) by 42.1% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 68,043 shares of the company’s stock after selling 49,495 shares during the period. Thrivent Financial for Lutherans owned approximately 0.06% of Henry Schein worth $4,970,000 at the end of the most recent quarter.

Other hedge funds have also added to or reduced their stakes in the company. Ameriprise Financial Inc. increased its position in shares of Henry Schein by 3,275.2% during the second quarter. Ameriprise Financial Inc. now owns 2,266,858 shares of the company’s stock worth $165,594,000 after acquiring an additional 2,199,695 shares in the last quarter. Norges Bank acquired a new position in Henry Schein in the 2nd quarter worth $89,476,000. M.D. Sass LLC bought a new position in Henry Schein during the 2nd quarter worth about $79,201,000. Schroder Investment Management Group raised its stake in shares of Henry Schein by 149.3% in the 2nd quarter. Schroder Investment Management Group now owns 1,563,899 shares of the company’s stock valued at $114,243,000 after purchasing an additional 936,471 shares during the period. Finally, Bank of America Corp DE lifted its holdings in shares of Henry Schein by 204.2% in the second quarter. Bank of America Corp DE now owns 995,375 shares of the company’s stock valued at $72,712,000 after purchasing an additional 668,182 shares in the last quarter. Institutional investors and hedge funds own 96.62% of the company’s stock.

Henry Schein Trading Up 0.4%

Shares of HSIC stock opened at $77.35 on Friday. Henry Schein, Inc. has a 12-month low of $60.56 and a 12-month high of $82.49. The company has a market capitalization of $9.11 billion, a PE ratio of 24.48, a price-to-earnings-growth ratio of 2.36 and a beta of 0.89. The firm has a 50 day moving average price of $70.43 and a two-hundred day moving average price of $69.77. The company has a quick ratio of 0.79, a current ratio of 1.40 and a debt-to-equity ratio of 0.54.

Henry Schein (NASDAQ:HSIC) last posted its earnings results on Tuesday, November 4th. The company reported $1.38 earnings per share for the quarter, topping analysts’ consensus estimates of $1.27 by $0.11. The company had revenue of $3.34 billion during the quarter, compared to the consensus estimate of $3.28 billion. Henry Schein had a return on equity of 14.76% and a net margin of 3.02%.Henry Schein has set its FY 2025 guidance at 4.880-4.960 EPS. As a group, analysts predict that Henry Schein, Inc. will post 4.74 earnings per share for the current year.

Analyst Ratings Changes

A number of research firms recently issued reports on HSIC. Weiss Ratings reiterated a “hold (c)” rating on shares of Henry Schein in a report on Tuesday. Wells Fargo & Company lifted their price objective on shares of Henry Schein from $70.00 to $76.00 and gave the company an “equal weight” rating in a report on Wednesday, November 5th. Morgan Stanley boosted their price objective on shares of Henry Schein from $55.00 to $58.00 and gave the stock an “underweight” rating in a research report on Wednesday, November 5th. Barclays initiated coverage on shares of Henry Schein in a research report on Monday, December 8th. They issued an “overweight” rating and a $86.00 target price for the company. Finally, JPMorgan Chase & Co. boosted their price target on shares of Henry Schein from $76.00 to $78.00 and gave the stock an “overweight” rating in a research report on Wednesday, November 5th. Six research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $76.92.

About Henry Schein

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.